p53 protein expression and DNA ploidy in common epithelial tumors of the ovary

Acta Cytologica

Volumn 41, Issue 6, 1997, Pages 1714-1718

  Ioakim Liossi, Anna ^a,b,c   Karakitsos, Petros ^a,b,c   Aroni, Kyriaki ^a,b,c   Delivelioti, Kalliopi ^a,b,c   Fotiou, Vassiliki ^a,b,c   Fotiou, Stelios ^a,b,c   Kyrkou, Kalliopi ^a,b,c  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c 1st Department of Medical Oncology   (Greece)

Author keywords

DNA; Immunocytochemistry; Ovarian neoplasms; p53 protein; Ploidies

Indexed keywords

AVIDIN; PROTEIN P53;

ADULT; ADVANCED CANCER; AGED; ANEUPLOIDY; ARTICLE; CANCER GRADING; CHROMOSOME 17; DNA CONTENT; EPITHELIUM TUMOR; FEMALE; HUMAN; IMMUNOCYTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY TUMOR; PLOIDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE;

EID: 0030665393     PISSN: 00015547     EISSN: 19382650     Source Type: Journal    
DOI: 10.1159/000333174     Document Type: Article

References (27)

1. Auer G, Steinbeck R, Zetterberg A: Molecular markers in diagnostic pathology. In The Computerized Cytology and Histology Laboratory. Edited by GL Wied, PH Bartels, DL Rosenthal, U Schenck. Chicago, Tutorials of Cytology, 1994, pp 129-142
2. Bartek J, Bartkova J, Lukas J, Staskova Z, Vojtesek B, Lane DP: Immunohistochemical analysis of the p53 oncoprotein in paraffin sections using a series of novel monoclonal antibodies. J Pathol 1993;169:27-34
3. Decker DG, Malkasian GD, Taylor WF: Prognostic importance of histologic grading in ovarian carcinoma. In Symposium on Ovarian Carcinoma. Edited by JC Bailar III. Washington, DC, US Government Printing Office, 1975, pp 9-11
4. Diller L, Kassel J, Nelson CE, Gzyka MA, Litwek G, Gebhardt M, Bressac B, Ozturk M, Baker SJ, Vogelstein B: p53 Function as a cell cycle control protein in osteosarcomas. Mol Cell Biol 1990;10:5772-5781
5. Dowell SP: p53 Immunocytochemical staining in diagnostic cytopathology: The relevance of the proportion of positive cells. Cytopathology 1995;6:358-362
6. Dowell SP, Wilson POG, Derias NW, Lane DP, Hall PA: The clinical utility of the immunocytochemical detection of p53 protein in cytological specimens. Cancer Res 1994;54:2914-2918
7. Eccles DM, Brett L, Lessells A, Gruber L, Lane D, Steel CM, Leonard RC: Overexpression of the p53 protein and allele loss at 17p13 in ovarian carcinoma. Br J Cancer 1992;65:40-44
8. Friendlander HL, Hedley DW, Swanson C, Russell P: Prediction of long term survival by flow cytometric analysis of cellular DNA content in patients with advanced ovarian cancer. J Clin Oncol 1988;6:282-290
9. Hall PA, Ray A, Lemoine NR, Midgley CA, Krausz T, Lane DP: p53 Immunostaining as a marker of malignant disease in diagnostic cytopathology (lett). Lancet 1991;338:513
10. Hollstein M, Sidransky D, Vogelstein B, Harris CC: p53 Mutations in human cancers. Science 1991;253:49-53
11. Iversen OE, Staarland C: Ploidy assessment of benign and malignant ovarian tumours by flow cytometry. Cancer 1987;60:82-87
12. Kihana T, Tsuda H, Teshima S, Okada S, Matsuura S, Hirhashi S: High incidence of p53 gene mutation in human ovarian cancer and its association with nuclear accumulation of p53 protein and tumor DNA aneuploidy. Jpn J Cancer Res 1992;83:978-984
13. Kiyokawa T: Alteration of p53 in ovarian cancer: Its occurrence and maintenance in tumor progression. Int J Gynecol Pathol 1994;13:311-318
14. Klemi PJ, Joensuu H, Kiilholma P, Maenpoa J: Clinical significance of abnormal DNA content in serous ovarian tumors. Cancer 1988;62:2005-2010
15. Klemi P, Takahashi S, Joensuu H, Kiilholma P, Narimatsu E, Mori M: Immunohistochemical detection of p53 protein in borderline and malignant serous ovarian tumors. Int J Gynecol Pathol 1994;13:228-233
16. Kohler MF, Kerns BJ, Humphrey PA, Marks JR, Bast RJ, Berchuck A: Mutation and overexpression of p53 in early-stage epithelial ovarian cancer. Obstet Gynecol 1993;81:643-650
17. Levine AJ, Momand J, Finlay CA: The p53 tumor suppressor gene. Nature 1991;351:453-456
18. Marchevsky AM, Bartels PH: Image Analysis: A Primer for Pathologists. New York, Raven Press, 1994, p 283
19. Marks JR, Davidoff AM, Kerns BJ, Humphrey PA, Pence JC, Dodge PK, Clarice PD, Iglehart JD, Bast RJ, Berchuck A: Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res 1991;5:2979-2984
20. Mazars R, Pujol P, Maudelonde T, Jeanteur P, Theillet C: p53 Mutations in ovarian cancer: A late event. Oncogene 1991;6:1685-1690
21. Mercer WE, Shields MT, Armin M, Sauve GJ, Appella E, Romano JW, Ullrich SJ: Negative growth regulation in glioblastoma tumor cell line that conditionally expresses wild type p53. Proc Natl Acad Sci USA 1990; 87:6166-6170
22. Miller C, Mohandas T, Wolf D, Prokocimer M, Rotter V, Ko-effler PH: Human p53 gene localized in short arm of chromosome 17. Nature 1986;319:783- 784
23. Sahni K, Tribukait B, Einhorn N: Flow cytometric measurement of ploidy and proliferation in effusions of ovarian carcinoma and their possible prognostic significance. Gynecol Oncol 1989;35:240-245
24. Serov SF, Scully RE, Sobin LH: Histological Typing of Ovarian Tumours. Geneva, World Health Organization, 1973, pp 37-42
25. Stepherd JH: Revised FIGO staging for gynaecological cancer. Br J Obstet Gynaecol 1989;96:889-892
26. Trope C, Kaern J: DNA ploidy in epithelial ovarian cancer: A new independent prognostic factor (edit)? Gynecol Oncol 1994;53:1-4
27. Vojstek B, Lane DP: Regulation of p52 expression in human breast cancer cell lines. J Cell Sci 1993;105:607-612